Jeffrey E. Lancet

15.2k citations

437 papers · 7.8k indexed · h-index 48

Impact in

Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 360
- Acute Myeloid Leukemia Research 334
- Chronic Myeloid Leukemia Treatments 89
- Multiple Myeloma Research and Treatments 36
Genetics 160
- Myeloproliferative Neoplasms: Diagnosis and Treatment 101
- Chronic Lymphocytic Leukemia Research 58

Co-authors: Rami S. Komrokji Alan F. List Eric Padron Judith E. Karp Kendra Sweet David A. Sallman Jonathan E. Kolitz Eric J. Feldman
Journals: Blood (219 papers)Journal of Clinical Oncology (28 papers)Leukemia Research (22 papers)American Journal of Hematology (9 papers)Clinical Cancer Research (8 papers)
Partner nations: United States France Canada

In The Last Decade

Jeffrey E. Lancet

409 papers receiving 7.7k citations

Peers

Countries citing papers authored by Jeffrey E. Lancet

Since Specialization

Citations

This map shows the geographic impact of Jeffrey E. Lancet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey E. Lancet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey E. Lancet more than expected).

Fields of papers citing papers by Jeffrey E. Lancet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey E. Lancet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey E. Lancet. The network helps show where Jeffrey E. Lancet may publish in the future.

Co-authors

The 25 scholars most cited alongside Jeffrey E. Lancet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeffrey E. Lancet Line = papers co-authored together Jeffrey E. Lancet links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML Annals of Hematology ·Akriti Jain, 一雄櫻井, Somedeb Ball, Gyuzel Sharipzyanova, Gustavo Tomazoli, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami S. Komrokji, David A. Sallman, Jeffrey E. Lancet, Javier Pinilla‐Ibarz, Kendra Sweet	2024	5
2	Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm SHILAP Revista de lepidopterología ·Zhuoer Xie, 美砂子川俣, Ling Zhang, Peter Papenhausen, Xueying Yuan, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Alison Walker, Firdevs Kulak Torun, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji	2024	0
3	Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting Blood ·Ronghua Huang, A Gisevius, Victor Julianto Simanullang, Jeffrey E. Lancet, Rami S. Komrokji, Javier Pinilla‐Ibarz, David A. Sallman, 雅人本間, Alison R. Walker, Julio C. Chávez, Xandie Thompson, Bijal Shah	2024	0
4	IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD) Blood ·Rami S. Komrokji, Najla H. Al Ali, Zhuoer Xie, Chandrashekhar Ingle, Sam Campbell, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Alison R. Walker, Jeffrey E. Lancet, Eric Padron, David A. Sallman	2024	0
5	Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience Blood ·Fatima Tuz Zahra, Rubén Zamudio, M.A.G., Onyee Chan, Ronghua Huang, Jeffrey E. Lancet, David A. Sallman, Rami S. Komrokji, Andrew Kuykendall, Eric Padron, Alison R. Walker, Zhuoer Xie, Seongseok Yun	2024	1
6	Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes Blood Advances ·Rami S. Komrokji, Luis E. Aguirre, Najla H. Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman	2023	7
7	Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients Cancer Communications ·Anna R. Giuliano, Barbara J. Kuter, Shari Pilon‐Thomas, Junmin Whiting, Qianxing Mo, Brett Leav, Bradley Sirak, Christopher Cubitt, Krishna Kanthi Gudimella, Padhi Sanjukta, Maurício Jonas Ferreira, Somedeb Ball, 氏川恵次, Akriti Jain, Patrick Hwu, Jeffrey E. Lancet	2023	6
8	Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes Blood ·Luis E. Aguirre, Akriti Jain, Somedeb Ball, Najla Al Ali, Sara Tinsley, David A. Sallman, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Andrew Kuykendall, Rami S. Komrokji	2021	7
9	Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes Blood ·David A. Sallman, Hany Elmariah, Kendra Sweet, Chetasi Talati, Asmita Mishra, Cheryl A. Cox, Roshanak Tolouei Semnani, Rutul R. Shah, Helen Sabzevari, C. Spano, Hans-Christof Kraus, Amy Lankford, Chen Wang, Eric Padron, Andrew Kuykendall, Rami S. Komrokji, Jeffrey E. Lancet, Marco L. Davila, Nelli Bejanyan	2021	21
10	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy Leukemia Research ·Chetasi Talati, Aaron D. Goldberg, Amanda Przespolewski, Onyee Chan, Najla Al Ali, Jongphil Kim, Radhi Maaoui, David A. Sallman, Eric Padron, Andrew Kuykendall, Jeffrey E. Lancet, Eunice S. Wang, Martin S. Tallman, Rami S. Komrokji, Kendra Sweet	2020	13
11	Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia Clinical Cancer Research ·Kendra Sweet, Rami S. Komrokji, Eric Padron, Christopher Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio C. Chávez, Bijal Shah, Jeffrey E. Lancet	2019	22
12	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Blood ·R. Coleman Lindsley, Christopher J. Gibson, H. Moses Murdock, Richard M. Stone, Jörge E. Cortes, Geoffrey L. Uy, Tara L. Lin, Ellen K. Ritchie, Thomas Prébet, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet	2019	27
13	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS Clinical Cancer Research ·Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey E. Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	2018	86
14	TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia Blood ·Aaron D. Goldberg, Chetasi Talati, Pinkal Desai, Christopher Famulare, Sean M. Devlin, Noushin Farnoud, David A. Sallman, Jeffrey E. Lancet, Gail J. Roboz, Kendra Sweet, Martin S. Tallman	2018	35
15	Gaining a Better Sense for ASXL1 Mutations in Myelofibrosis: Assessing the Variable Impact of Frameshift, Nonsense, and Missense Mutations Blood ·Andrew Kuykendall, Wei-Jie Wang, Chetasi Talati, Najla Al Ali, Kendra Sweet, David A. Sallman, Eric Padron, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji	2017	0
16	Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype Blood ·David A. Sallman, 王岗, Rami S. Komrokji, Kathy L. McGraw, Susan Geyer, Erika A. Eksioglu, Najla Al Ali, Jeffrey E. Lancet, Sheng Wei, Eric Padron, Alan F. List	2017	6
17	A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) Clinical Cancer Research ·Eric Padron, Amy E. DeZern, Marcio Andrade‐Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E. Balasis, Sara Tinsley, Shreya Soni -, J. Alexander Tanford, David P. Steensma, Gail J. Roboz, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji	2016	62
18	A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes Clinical Cancer Research ·Guillermo Garcia‐Manero, H. Jean Khoury, Elias Jabbour, Jeffrey E. Lancet, Shannon L. Winski, Kevin Barr, M. Hürbin, Lara Maloney, Adam R. Duffen, Mieke Ptaszynski, Mónica Cabrero, Zach Bohannan, Alan F. List, Hagop M. Kantarjian, Rami S. Komrokji	2014	40
19	Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome Blood ·Rami S. Komrokji, Jeffrey E. Lancet, Arlene S. Swern, Nianhang Chen, Yudith Dwi Angela, Richard M. Lush, Hussain I. Saba, Alan F. List	2012	47
20	Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia Clinical Cancer Research ·Mitch Raponi, Jean‐Luc Harousseau, Jeffrey E. Lancet, Bob Löwenberg, Richard M. Stone, Yi Zhang, Wayne Rackoff, Yixin Wang, David Atkins	2007	52

About Jeffrey E. Lancet

Jeffrey E. Lancet is a scholar working on Hematology, Genetics, Oncology, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 437 papers that have together received 7.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (334 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (101 papers), Chronic Myeloid Leukemia Treatments (89 papers), Acute Lymphoblastic Leukemia research (60 papers), Chronic Lymphocytic Leukemia Research (58 papers), Histone Deacetylase Inhibitors Research (39 papers), Multiple Myeloma Research and Treatments (36 papers) and Neutropenia and Cancer Infections (27 papers). The work is most often cited by research in Hematology (5.3k citations), Genetics (2.1k citations), Oncology (1.8k citations), Molecular Biology (3.5k citations) and Public Health, Environmental and Occupational Health (1.0k citations). Jeffrey E. Lancet has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Rami S. Komrokji, Alan F. List, Eric Padron, Judith E. Karp, Kendra Sweet, David A. Sallman, Jonathan E. Kolitz, Eric J. Feldman, Arthur C. Louie and Jörge E. Cortes. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia Research, American Journal of Hematology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact